Incontinence back under control
Certain is developing a patient-controlled, minimally invasive device for female stress urinary incontinence — positioned between pads and surgery.
A large, structurally underserved market.
A validated clinical gap.
A disciplined, capital-efficient development pathway.
Proof of Concept investment round now open (Q1 2026)
The problem we address
Structural momentum is building
The market is shifting due to:
Aging demographics and longer treatment horizons
Growing dissatisfaction with lifelong disposables
Continued aversion to invasive surgery
Rising pressure on healthcare systems
Increased focus on women’s health and sustainability
The system is ready for a durable, minimally invasive alternative.
Our solution
A persistent care gap in a large market
Female urinary incontinence affects tens of millions of women, yet care remains structurally inadequate.
Existing options force a trade-off:
Disposable products that mask symptoms
Conservative therapies with limited durability
Invasive surgery that many patients avoid
As a result, a large population is treated — but dissatisfied.
This is not a discovery problem.
It is a care-gap problem.
Why now…
A new option between pads and surgery
Certain is developing a physician-placed, patient-controlled intra-urethral device designed for long-term, reversible use.
The solution is:
Minimally invasive and outpatient-based
Positioned between disposable management and surgery
Designed for durability, patient autonomy, and reversibility
Intended to reduce dependency on lifelong disposables
Certain does not replace surgery.
It expands the treatment continuum for women seeking real continence without irreversible intervention.
Certain gives you control
No more leaks, no more smells, no more inconvenient situations. We bring back the natural feel of one of the most basic needs. We develop the most innovative and convenient solution for stress urinary incontinence without waste!
Follow our journey
Contact us
Want to know more about the product or looking for investment options? Please contact us!